Made to measure sugar-like molecule could improve cancer-fighting antibodies

May 17, 2018, Canadian Glycomics Network
Dr. Robert Britton in his Simon Fraser University lab in Burnaby, BC. Credit: B. Poitras, GlycoNet

Dr. Robert Britton firmly believes every molecule is important. This chemist doesn't want any molecule sitting unused on a laboratory shelf or in a fridge.

"I want every molecule to have a purpose—that's my ethos for our lab," says Britton, a GlycoNet network investigator and professor at Simon Fraser University.

With that spirit in mind, Britton has embarked on an ambitious project to develop carbohydrate mimics to assist therapies by making them more selective in how they target and kill .

In the 80s and 90s, it was recognized that traditional chemotherapies were limited as a result of the high systemic toxicity associated with targeting rapidly dividing cells. Researchers began to look at alternative approaches to specifically targeting cancer cells, including the development of antibodies which recognized and bound to proteins expressed on cancer cells.

This research led to the development and approval of the first two monoclonal antibodies (mAbs) for use in cancer therapy: rituximab (Rituxan) for non-Hodgkin's lymphoma in 1997 and trastuzumab (Herceptin) for breast cancer in 1998. Herceptin changed HER2+ breast cancer from a fatal disease where patients had a small chance of survival to one that is highly treatable

Britton's work focuses on the binding of the antibody to the cancer cell which leads to the recruitment of Natural killer cells and results in Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). ADCC is a critical mechanism underlying the clinical efficacy of therapeutic anticancer antibodies. After the cancer cell is terminated, the human body will naturally get rid of it.

However, researchers have now identified that when antibodies have fucose molecules attached (i.e. are fucosylated), they have lower levels of ADCC as the antibody's ability to attract immune is impeded, and studies have shown that removal/prevention of the fucosylation from antibody therapeutics elicits high ADCC.

"There has been a lot of effort and investment into ways to prevent fucosylation of antibodies so you can improve cytotoxicity," says Britton.

"The challenge in creating these molecules is that, while some companies are successful in inhibiting the transfer of fucose to the antibody, the inhibitor itself becomes attached to the antibody which may represent an imunogen and presents significant drug consistency risks"

Britton explains the goal of his project is to develop fucosylation inhibitors that do not transfer themselves to the antibody.

These molecules, fucosylation inhibitors, are what Britton and his research group are trying to identify and create. GlycoNet funding will provide the means to develop this set of inhibitors in the form of a Catalyst grant.

"These aren't simple molecules to make," says Britton. "They take real expertise, so GlycoNet funding allows us to hire highly qualified personnel to work on this project for one year. We couldn't do this without GlycoNet—it takes a lot of time, energy and expertise."

"We're excited by the prospect of Dr. Britton's research and we see the potential to translate this research into a practical, medical application," says Dr. Todd Lowary, Scientific Director of GlycoNet. "Dr. Britton's lab has the expertise and knowledge to produce these inhibitors and make this project a success."

While Britton's lab has a defined expertise in creating new molecules—20 researchers strong and a long history in chemical synthesis—producing these inhibitors for medicinal chemistry is a new direction for them.

Scaling up the synthesis will be a challenge, but if his lab is successful Britton hopes to attract industrial partners to test the inhibitors with antibodies for stability and cytotoxicity.

Once that happens, Britton says the next step is to license the inhibitors for commercialization.

"Because these are going into the production of antibodies, there is a much clearer path from discovery to commercialization," says Britton. "If we can produce a good inhibitor, we anticipate a quick uptake from companies that would use it to produce these cancer-fighting ."

Explore further: Technique to generate antibodies for natural immune responses to cancer and leukemia

Related Stories

Technique to generate antibodies for natural immune responses to cancer and leukemia

March 23, 2016
The artificial enhancement of the body's natural immune defenses is a potential weapon in the battle against diseases such as leukemia. A*STAR researchers are honing methods to boost the interactions between antibodies and ...

Engineering a safer antibody drug

May 2, 2018
An innovative approach to protein engineering could help make antibody-based drug therapies less toxic and more effective.

Disease-fighting antibody production

April 20, 2018
The influence of environmental cues on the differentiation and function of B cells—white blood cells that produce antibodies as part of humoral immunity—is incompletely understood.

Inhibitors support immune therapy for leukemia

September 12, 2017
New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from ...

Halting liver cancer with a sugar look-a-like

October 12, 2017
Researchers at the RIKEN Global Research Cluster in Japan have discovered a way to prevent the spread of cancer in the liver. Published in the journal Cell Chemical Biology, the study details how treatment with a modified ...

Recommended for you

Scientists discover how breast cancer hibernates: study

May 22, 2018
Scientists have identified the mechanism that allows breast cancer cells to lie dormant in other parts of the body only to reemerge years later with lethal force, according to a study published Tuesday.

Researcher: Big data, networks identify cell signaling pathways in lung cancer

May 22, 2018
A team of scientists led by University of Montana cell biologist Mark Grimes has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Downward-facing mouse: Stretching reduces tumor growth in mouse model of breast cancer

May 22, 2018
Many cancer patients seek out gentle, movement-based stretching techniques such as yoga, tai chi and qigong, but does stretching have an effect on cancer? While many animal studies have attempted to quantify the effects of ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.